American Society of Hematology

Figure 1.

Analysis of human HSPCs expanded using SR1 in vitro. (A) 5.0 × 103 MACS-enriched CD34+ HSPCs per mL were cultured in the presence of 0.75 μM of SR1 for 15 days before T-progenitor expansion for 14 days on irradiated OP9-DL1 cells. (B) Total nuclear cells for day 7 and day 15 of SR1 culture. (C) Phenotypic analysis by flow cytometry of CD34 and CD38, and corresponding total numbers of CD34+CD38−/lo cells at day 7 or day 15 of SR1 culture. (D) Phenotypic analysis by flow cytometry of CD34 and CD90, and corresponding total numbers of CD34+CD90+ cells at day 7 or day 15 of SR1 culture. Error bars correspond to standard error of the mean. *P < .05, representing statistical significance compared with day 0 as determined by nonparametric Friedman test with post hoc Dunn’s analysis. SFEM, Serum-Free Expansion Medium; TPO, thrombopoietin.

Analysis of human HSPCs expanded using SR1 in vitro. (A) 5.0 × 10³ MACS-enriched CD34⁺ HSPCs per mL were cultured in the presence of 0.75 μM of SR1 for 15 days before T-progenitor expansion for 14 days on irradiated OP9-DL1 cells. (B) Total nuclear cells for day 7 and day 15 of SR1 culture. (C) Phenotypic analysis by flow cytometry of CD34 and CD38, and corresponding total numbers of CD34⁺CD38^−/lo cells at day 7 or day 15 of SR1 culture. (D) Phenotypic analysis by flow cytometry of CD34 and CD90, and corresponding total numbers of CD34⁺CD90⁺ cells at day 7 or day 15 of SR1 culture. Error bars correspond to standard error of the mean. *P < .05, representing statistical significance compared with day 0 as determined by nonparametric Friedman test with post hoc Dunn’s analysis. SFEM, Serum-Free Expansion Medium; TPO, thrombopoietin.

This Feature Is Available To Subscribers Only